In which scenario would PTH receptor agonists be used?

In which scenario would PTH receptor agonists be used?

• A. For patients with mild osteoporosis
• B. For patients at high risk for vertebral fractures
• C. For patients with no history of fractures
• D. For patients with low calcium intake

Answer: (B)

PTH receptor agonists, such as teriparatide, are used specifically for patients who are at high risk for vertebral fractures. These drugs work by mimicking the action of parathyroid hormone, which plays a significant role in bone metabolism. The agonists stimulate bone formation and increase osteoblastic activity, leading to an increase in bone mineral density, particularly in patients who have already experienced fractures or who have a very high risk of sustaining fractures. This treatment approach is especially beneficial for those with a significant history of fractures or those diagnosed with severe osteoporosis, as it can help to significantly reduce the risk of further fractures. In the context of the options provided, it is clear that patients at high risk for vertebral fractures would benefit the most from PTH receptor agonists because their condition poses an immediate need for intervention to prevent further skeletal complications.

PTH receptor agonists, such as teriparatide, are used specifically for patients who are at high risk for vertebral fractures. These drugs work by mimicking the action of parathyroid hormone, which plays a significant role in bone metabolism. The agonists stimulate bone formation and increase osteoblastic activity, leading to an increase in bone mineral density, particularly in patients who have already experienced fractures or who have a very high risk of sustaining fractures.

This treatment approach is especially beneficial for those with a significant history of fractures or those diagnosed with severe osteoporosis, as it can help to significantly reduce the risk of further fractures. In the context of the options provided, it is clear that patients at high risk for vertebral fractures would benefit the most from PTH receptor agonists because their condition poses an immediate need for intervention to prevent further skeletal complications.